BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
CD30-directed Antibody Interactions
Pharmacologic Class:
CD30-directed Immunoconjugate
Indications (25)
IV cHLcombination with doxorubicinvinblastinedacarbazineolder with previously untreated high risk cHLvincristineetoposideprednisonecyclophosphamideprogressionafter failure of at least two prior multi-agent chemotherapy regimens in patientsother CD30-expressing PTCLincluding angioimmunoblastic T-cell lymphomaPTCL not otherwise specified (NOS)combination with cyclophosphamidedoxorubicinCD30-expressing MFrefractory LBCLincluding diffuse large B-cell lymphoma (DLBCL) NOSDLBCL arising from indolent lymphomahigh-grade B-cell lymphoma (HGBL)after twomore lines of systemic therapychimeric antigen receptor (CAR) T-cell therapylymphoma
Clinical Trials (5)
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Started Aug 2024
124 enrolled
Hodgkin Lymphoma
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Started Feb 2024
11 enrolled
Diffuse Cutaneous Systemic Sclerosis
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
Started Feb 2024
26 enrolled
T-Cell Lymphoma
A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone
Started Dec 2023
0Hodgkin Lymphoma
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Started Dec 2023
25 enrolled
Hodgkin Lymphoma